RISEDRONATE ZENTIVA K.S. 35 mg, film-coated tablet 12 tablets
Active ingredients: Risedronic acid, Risedronate sodium
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet12 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- RISEDRONATE ZENTIVA K.S. 35 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC polyéthylène PVDC aluminium de 12 comprimé(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 23 Dec 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68593411CIP73018855CIP133400930188552Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RISÉDRONATE MONOSODIQUE ANHYDREcomprimé | 35 mg · un comprimé | SA |
| ACIDE RISÉDRONIQUEcomprimé | 32,5 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.